In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alkermes PLC

www.alkermes.com

Latest From Alkermes PLC

FDA Wins Abilify Exclusivity Battle; Court Rejects Otsuka's 'Legal Equivalence'

Otsuka claimed Alkermes' Aristada is 'legally equivalent' to Abilify but DC Circuit deferred to FDA's finding that the two have different active moieties and thus Abilify's three-year exclusivity does not apply to Aristada.

Intellectual Property Legal Issues

Neuralstem Plans Deep Dive Into Failed Phase II Major Depression Trial

Failure of NSI-189 in major depression study sends stock price down about 50% and next steps for development are unclear.

Neurology Clinical Trials

Lilly, Nektar Partner On 'Stimulating' IL-2 Drug In Autoimmune Diseases

Nektar taps into Lilly's immunology know-how for fast development of NKTR-358, which targets IL-2 to stimulate the body's own inflammation-inhibiting Tregs rather than suppress the immune system.

Deals Business Strategies

Pipeline Watch: Phase III Starts With Mogamulizumab, AR101 And Vilaprisan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Pulmonary
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Alkermes Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Alkermes PLC
  • Senior Management
  • Richard F Pops, Chmn. & CEO
    James M Frates, SVP, CFO
    Elliot W Ehrich, MD, EVP, R&D & CMO
    Blair C Jackson, VP, Bus. Dev.
    Mark Stejbach, SVP, Chief Commercial Officer
  • Contact Info
  • Alkermes PLC
    Phone: 1 772 8000
    1 Burlington Rd.
    Connaught House
    Dublin 4, MA
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register